SLS vs. AUP, BHC, CARA, CRON, TEV, ABT, NOT, PYR, NVO, and DNA
Should you be buying Solaris Resources stock or one of its competitors? The main competitors of Solaris Resources include Aurinia Pharmaceuticals (AUP), Bausch Health Companies (BHC), Cara Operations (CARA), Cronos Group (CRON), Tervita (TEV), Absolute Software Co. (ABT.TO) (ABT), Noront Resources (NOT), PyroGenesis Canada Inc. (PYR.V) (PYR), Novo Resources Corp. (NVO.V) (NVO), and Dalradian Resources (DNA). These companies are all part of the "pharmaceutical products" industry.
Solaris Resources vs. Its Competitors
Aurinia Pharmaceuticals (TSE:AUP) and Solaris Resources (TSE:SLS) are both computer and technology companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, community ranking, dividends and institutional ownership.
In the previous week, Solaris Resources had 1 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 1 mentions for Solaris Resources and 0 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 0.00 equaled Solaris Resources'average media sentiment score.
Solaris Resources has a consensus target price of C$13.88, indicating a potential upside of 129.72%. Given Solaris Resources' stronger consensus rating and higher possible upside, analysts plainly believe Solaris Resources is more favorable than Aurinia Pharmaceuticals.
Aurinia Pharmaceuticals received 232 more outperform votes than Solaris Resources when rated by MarketBeat users. Likewise, 72.22% of users gave Aurinia Pharmaceuticals an outperform vote while only 50.00% of users gave Solaris Resources an outperform vote.
Solaris Resources has lower revenue, but higher earnings than Aurinia Pharmaceuticals. Solaris Resources is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Aurinia Pharmaceuticals' return on equity of 0.00% beat Solaris Resources' return on equity.
25.1% of Solaris Resources shares are owned by institutional investors. 40.6% of Solaris Resources shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Solaris Resources beats Aurinia Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
Get Solaris Resources News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Solaris Resources Competitors List
Related Companies and Tools
This page (TSE:SLS) was last updated on 6/13/2025 by MarketBeat.com Staff
Buy SLS Stock Free SLS Stock Alerts